Alaunos Therapeutics Inc. stocks have been trading up by 64.76 percent amid heightened optimism over its latest cancer therapy developments.
Click Here for a Millionaire's POV on Trading TCRT
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- TCRT is bouncing hard off recent lows, with Alaunos Therapeutics Inc. reclaiming the $1 area after heavy selling pressure in prior sessions.
- Intraday action shows a huge premarket spike from below $1 to above $2, signaling aggressive momentum trading and high volatility in TCRT.
- Financials reveal minimal revenue and steep losses, so TCRT remains a pure speculative biotech trading vehicle, not a value play.
- Liquidity looks tight, with low cash and negative working capital, making dilution or financing a constant overhang for TCRT traders.
Live Update At 08:34:10 EDT: On Tuesday, October 13, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 64.76%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Alaunos Therapeutics Inc., trading under ticker TCRT, is a classic micro-cap biotech battleground name. On the fundamentals side, revenue is basically a rounding error at just $5,000, yet the market is pricing the company at a rich price-to-sales ratio near 956. That tells traders right away: this is all story, hope, and volatility, not cash flow.
The latest quarter shows a net loss of about $952,000 and negative free cash flow of $300,000. Alaunos Therapeutics Inc. ended the period with only $124,000 in cash and working capital of roughly -$198,000, meaning current liabilities outweigh current assets. With a current ratio of 0.8 and a quick ratio of 0.1, TCRT has very little cushion.
More Breaking News
- SCNI Stock Stabilizes As Nasdaq Compliance Risk Fades
- FRMI Stock Slides As Cash Burn And Debt Pressure Mount
- BTBT Stock Drifts Lower As Charts Flag Key Support
- QTEX Quantum Slides 13% Premarket As Volatility Spikes
On the flip side, TCRT carries no long-term debt, which is one small plus. But return on equity and return on assets are deeply negative, underscoring how early-stage and unprofitable this business remains. For traders, that mix — tiny revenue, heavy losses, thin cash — usually translates into a high-risk, high-volatility chart that lives and dies on sentiment and momentum.
Why Traders Are Watching TCRT’s Volatile Chart
The main reason active traders are glued to TCRT right now is the wild price action. On the daily chart, Alaunos Therapeutics Inc. spent late September trading around $1.20–$1.30 before fading steadily into early October, sliding under $0.80. That drift lower set up a classic beaten-down biotech look — weak trend, low price, and plenty of shorts leaning on it.
Then the character changed. On 2026/10/12, TCRT opened near $0.78 and ripped to a $1.05 close, tagging the day’s high. That’s a strong bullish reversal after several red or choppy sessions. For short-term traders, a close at the high of the day after a downtrend is a big tell that momentum is shifting.
The intraday 5‑minute chart takes it to another level. Alaunos Therapeutics Inc. traded under $1 in the very early premarket, then exploded from around $1.00–$1.20 to the mid‑$2s in less than three hours. TCRT printed wild candles with ranges of $0.30–$0.60 in minutes, which is exactly the kind of action momentum traders hunt.
This kind of move in TCRT says one thing: the float is thin, liquidity is fragile, and when volume pours in, price can go vertical. But the same works on the downside. Traders who chase Alaunos Therapeutics Inc. without a plan risk getting trapped in violent pullbacks. For disciplined day traders, though, TCRT is a clean case study in how oversold biotech names can ignite when buyers finally show up.
Conclusion
TCRT sits at the intersection of weak fundamentals and powerful price action — exactly where short-term traders like to play. Alaunos Therapeutics Inc. has almost no revenue, a history of large losses, and very limited cash on the balance sheet. Ratios like negative ROE, negative ROA, and a thin current ratio tell you this is not a stable, cash‑generating biotech giant. It is a tiny, speculative story stock.
Yet that’s why the chart matters so much. When a name like TCRT drops from the $1.20s to the $0.70s and then rips back through $1 with a premarket spike above $2, it becomes a magnet for day traders and swing traders hunting range and volatility. Alaunos Therapeutics Inc. now has clear levels: sub‑$1 as support, the $1.50–$2 zone as a high‑risk, high‑reward battlefield.
The key is discipline. As Tim Sykes likes to hammer home, “The pattern is your edge, but risk management is your paycheck.” As Tim Bohen, lead trainer with StocksToTrade says, “If you’re still guessing at the end of your analysis, it’s probably not a trade worth taking.” With TCRT, the pattern is there — big range, shifting momentum, crowded short side. For traders willing to study the chart, respect the risk, and cut losses fast, Alaunos Therapeutics Inc. offers a live, real‑time education in how speculative biotech trading really works.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.